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SUMMARY
In response to DNA damage, eukaryotic cells activate ATM-Chk2 and/or ATR-Chk1 to arrest the cell
cycle and initiate DNA repair. We show that, in the absence of p53, cells depend on a third cell-cycle
checkpoint pathway involving p38MAPK/MK2 for cell-cycle arrest and survival after DNA damage.
MK2 depletion in p53-deficient cells, but not in p53 wild-type cells, caused abrogation of the
Cdc25A-mediated S phase checkpoint after cisplatin exposure and loss of the Cdc25B-mediated
G2/M checkpoint following doxorubicin treatment, resulting in mitotic catastrophe and pronounced
regression of murine tumors in vivo. We show that the Chk1 inhibitor UCN-01 also potently inhibits
MK2, suggesting that its clinical efficacy results from the simultaneous disruption of two critical
checkpoint pathways in p53-defective cells.INTRODUCTION
In response to DNA damage, eukaryotic cells activate
a complex signaling network to arrest the cell cycle and
facilitate DNA repair (Kastan and Bartek, 2004; Zhou and
Elledge, 2000). This signaling network has traditionally
been divided into two major protein kinase pathways,
one mediated by Ataxia-Telangiectasia mutated (ATM)
through Chk2, and the other mediated by Ataxia-Telangi-
ectasia and Rad-3-related (ATR) through Chk1 (Bartek
and Lukas, 2003; Shiloh, 2003). Some crosstalk exists
between the ATM/Chk2 and ATR/Chk1 kinase pathways,
particularly when signaling through one pathway is
partially or totally deficient (Bartek and Lukas, 2003).
Normally, however, the pathways show only partial
functional overlap in response to particular forms of DNA
damage. The ATM/Chk2 pathway responds primarily toCancDNA double-strand breaks (DSBs), while the ATR/Chk1
pathway is activated by bulky DNA lesions, and following
replication fork collapseduringSphase (Zhou andElledge,
2000).
The tumor suppressor protein p53 is a major down-
stream effector of these DNA-damage kinase pathways
(Harris and Levine, 2005). In normal cells, p53-dependent
signaling results in G1 arrest, mainly mediated by tran-
scriptional upregulation of p21 (Vogelstein et al., 2000). In
addition, p21 also appears to play a role in sustaining the
G2 checkpoint after g-irradiation (Bunz et al., 1998). If the
DNA damage is extensive, however, then p53-dependent
pathways target the damaged cell for apoptotic cell death
through both the intrinsic and extrinsic pathways (Fridman
and Lowe, 2003; Vousden and Lu, 2002). Most tumor cells
show specific disruptions in the p53 pathway (Vogelstein
et al., 2000), leading to selective loss of the G1 checkpoint.SIGNIFICANCE
Many anticancer agents induce DNA damage as part of their mechanism for tumor cytotoxicity. Here we show that
DNA-damaging chemotherapeutic drugs directly activate the p38MAPK/MK2 pathway downstream of ATM and
ATR. In p53-proficient cells, signaling through thispathway isdispensable for survival afterDNAdamage. Inmarked
contrast, however, activation of this pathway is essential for preventing chemotherapy-mediated cell death in p53-
deficient cells. The finding that cells that lack functional p53 become dependent on recruiting a general stress
kinase pathway to control the cell cycle rationalizes the therapeutic targeting of MK2 as a strategy to selectively
kill p53-defective tumor cells with low-dose chemotherapy.er Cell 11, 175–189, February 2007 ª2007 Elsevier Inc. 175
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MK2-Dependent Checkpoints in p53-Defective CellsThese cells are then entirely dependent on intra-S and
G2/M checkpoints to maintain their genomic integrity in
response to DNA damage.
In contrast to the DNA-damage-specific activation of
Chk1 and Chk2, the p38MAPK pathway is a general
stress-activated kinase pathway that responds to various
cellular stimuli, including cytokines, hyperosmolarity, and
UV irradiation (Roux and Blenis, 2004). Fornace and col-
leagues recently reported that p38MAPK activity was
important for G2/M checkpoint function in immortalized
fibroblasts and HeLa cells following UV exposure (Bulavin
et al., 2001). We found that MAPKAP Kinase-2 (MK2) was
the critical downstream effector kinase of p38MAPK re-
quired for UV-induced cell-cycle checkpoints in U2OS
cells (Manke et al., 2005).Whether the observed activation
of p38MAPK/MK2 is a direct result of UV-induced DNA
lesions, or results instead from other nongenotoxic effects
of UV radiation, is not known. Similarly, it is unclear
whether the p38MAPK/MK2 pathway is an important part
of a general cellular response to genotoxic stress, and if
it is, how this stress kinase pathway interconnects with
more canonical DNA-damage kinases that control cell-
cycle progression and DNA repair.
We now report that the p38MAPK/MK2 stress kinase
pathway is activated in response to the commonly used
DNA-damaging agents cisplatin, doxorubicin, and camp-
tothecin and that its cell-cycle checkpoint function is
essential in cells with defective p53. We go on to show
that both Chk1 and MK2 are activated independently of
each other, and that UCN-01, a small molecule currently
in clinical trials for cancer therapy, directly inhibits both
MK2 and Chk1 at similar concentrations.
RESULTS
The p38MAPK-MK2 Pathway Is Activated by Drugs
that Directly Damage DNA
To investigate whether the p38MAPK/MK2 pathway was
involved in the DNA-damage response of cells following
exposure to clinically useful chemotherapeutic agents,
we treated human U2OS osteosarcoma cells with the
DNA crosslinking agent cis-Platinum (cisplatin), the topoi-
somerase I inhibitor camptothecin, or the topoisomerase
II inhibitor doxorubicin (Figure 1). p38MAPK activation
was assessed using an antibody specific for the Thr-180/
Tyr-182 doubly phosphorylated active form of the kinase.
Activation of MK2 was monitored by its altered mobility
on SDS-PAGE, and by immunoblotting using a phospho-
specific antibody for pThr-334, a site in the autoinhibitory
domain whose phosphorylation by p38MAPK results in a
dramatic elevation of MK2 activity (Ben-Levy et al., 1995;
Engel et al., 1995).
Prior to exposure of cells to DNA-damaging compounds
(Figures 1A–1C, 0 hr lanes), or in cells treated with DMSO
(vehicle) alone (Figure 1D), MK2 ran as a single band that
did not crossreact with the anti-pThr-334 antibody. Within
1 hr after exposure of the cells to cisplatin anddoxorubicin,
or within 4 hr following treatment with camptothecin, MK2
displayed a significant reduction in its electrophoretic176 Cancer Cell 11, 175–189, February 2007 ª2007 Elsevier Inmobility. The upshiftedMK2 band appearedwith the same
kinetics as both the MK2 pThr-334 and the p38MAPK
pThr-180/pTyr-182 immunoreactive bands. Activation of
MK2 was entirely dependent on p38MAPK, since addi-
tion of the p38MAPK-selective inhibitor SB203580 to the
growth media 30 min prior to application of the DNA-
damaging agents completely abolished MK2 activation,
while preserving activation of p38MAPK (Figure 1E). Simi-
lar results for MK2 activation in response to cisplatin,
camptothecin, and doxorubicin were also observed in
HeLa cervical carcinoma cells, U87MG human glioblas-
toma cells, and primary MEFs (Figure 2A and data not
shown). The time course ofMK2 activation upon treatment
with each of these drugs (Figures 1A–1D)matched the rate
of appearance of g-H2AX nuclear foci (Figure 1F). These
data indicate that treatment of cells with these genotoxic
agents results in MK2 activation, likely as a direct result
of chemotherapy-induced DNA damage.
ATM and ATR Are Required for p38MAPK/MK2
Activation following Genotoxin-Induced DNA
Damage but Not in Response to UV Irradiation
We analyzed the p38MAPK/MK2 activation profile in
ATM-deficient and ATR-defective fibroblasts (O’Driscoll
et al., 2003) (Figures S1A–S1D and S2 in the Supplemental
Data available with this article online; Figure 1G). We also
studied the effect of pharmacological inhibition of these
kinases by addition of caffeine (Figures S1E and S1F).
Activation of the p38MAPK/MK2 complex in response to
cisplatin, camptothecin, or UV exposure occurred nor-
mally in ATM-deficient fibroblasts, while doxorubicin treat-
ment failed to activate either p38MAPK or MK2 in these
cells. ATR-defective fibroblasts, on the other hand, failed
to activate p38MAPK or MK2 following either cisplatin,
doxorubicin, or camptothecin exposure. However, UV-
inducedp38MAPK/MK2 activation in these cellswas unaf-
fected. Similarly, treatment of U2OS cells with 20 mM
caffeine, a concentration sufficient to inhibit ATM, ATR,
and DNA-PK (Block et al., 2004; Sarkaria et al., 1999), for
30min prior to exposure to cisplatin and doxorubicin com-
pletely abrogated the p38MAPK/MK2 response, while the
activation of these kinases by UV occurred normally under
these conditions. Taken together, these data indicate that
cisplatin, camptothecin, and doxorubicin require ATR for
p38MAPK/MK2 activation; that doxorubicin also requires
ATM activity; and that UV irradiation is capable of activat-
ing the p38MAPK/MK2 in a manner that is independent of
ATM, ATR, or DNA-PK function.
Loss of p53 Renders Cells Dependent on MK2
Signaling for Survival after Chemically
Induced DNA Damage
The p53 tumor suppressor protein plays an important
role in the cellular response to DNA damage by transcrip-
tionally upregulating the Cdk inhibitor p21 to induce a G1
and G2 arrest (Bartek and Lukas, 2001; Bunz et al., 1998;
Vogelstein et al., 2000). Cancer cells frequently show dis-
ruptions in the p53 pathway, eliminating this component
of the DNA-damage response, and leaving the cellsc.
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MK2-Dependent Checkpoints in p53-Defective CellsFigure 1. The p38MAPK/MK2 Pathway Is Activated by DNA-Damaging Drugs
(A–D) Kinetics of p38MAPK and MK2 activation. U2OS cells were treated with 10 mM cisplatin (A), 10 mM camptothecin (B), 10 mM doxorubicin (C),
or DMSO control (D) for the indicated times. Cell lysates were probed for total and phosphorylated/activated forms of p38MAPK and MK2 (MK-2)
by Western blotting. b-actin served as a loading control.
(E) MK2 activation is p38MAPK dependent. U2OS cells were treated with the p38MAPK-specific inhibitor SB203580 (10 mM) or DMSO vehicle for
30 min prior to exposure to chemotherapeutic drugs as in (A)–(D). Total and phosphorylated/activated p38 and MK2 were determined by immuno-
blotting as above.
(F) Activation of MK2 parallels the formation of gH2AX nuclear foci. U2OS cells were either mock treated or incubated with cisplatin (10 mM), camp-
tothecin (10 mM), or doxorubicin (10 mM). Cells were immunostained 1 and 4 hr later using an antibody against g-H2AX and counterstained with DAPI.
Scale bar, 2 mm.
(G) Summary of the requirement for ATM and/or ATR for the activation of MK2.Cancer Cell 11, 175–189, February 2007 ª2007 Elsevier Inc. 177
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MK2-Dependent Checkpoints in p53-Defective CellsFigure 2. p53-Deficient MEFs Require
MK2 for Survival after DNA Damage
(A) p21 induction is independent of MK2 acti-
vation. p53WT/WT and p53/ MEFs stably
expressing luciferase shRNA or MK2 shRNA
were treated with 10 mM cisplatin or 10 mM
doxorubicin. MK2 activation and components
of the p53 pathway were monitored by SDS-
PAGE and Western blot analysis.
(B and C) Clonogenic survival assay. p53WT/WT
and p53/ MEFs stably expressing luciferase
shRNA or MK2 shRNA were mock treated or
treated with increasing doses of cisplatin (B)
or doxorubicin (C) for 4 hr, washed in PBS,
trypsinized, and replated at 5000 cells/10 cm
dish. Fourteen days later, surviving colonies
were fixed, stained with crystal violet, and
counted. Assays were performed in triplicate
for each condition and normalized to mock-
treated cells. Mean values with error bars
denoting standard error of the mean are
shown. Asterisks denote statistically signifi-
cant differences (two-tailed Student’s t test,
p < 0.04).entirely dependent on remaining checkpoint signal-
ing pathways (Dixon and Norbury, 2002; Kawabe, 2004).
To examine whether the ATR/ATM-p38MAPK-MK2
pathway was required for cell survival after genotoxin-
induced DNA damage in p53 wild-type and p53/
MEFs, we used RNAi to deplete MK2 and examined the
response of these otherwise genetically identical cells to
cisplatin and doxorubicin using a colony survival assay
(Figure 2).
Cells were infected with lentiviruses delivering shRNAs
against luciferase (control) or MK2 and analyzed 6 days
later (Figure 2A). Luciferase and MK2 knockdown MEFs
were then exposed to increasing doses of cisplatin or
doxorubicin. As seen in Figures 2B and 2C, there was no
difference in the number of surviving colonies in the
p53WT/WT MEFs, regardless of the presence or absence
of MK2, at any dose of cisplatin or doxorubicin examined.
In contrast, downregulation ofMK2 inp53/ cells dramat-178 Cancer Cell 11, 175–189, February 2007 ª2007 Elsevier Inc.ically reduced the number of surviving colonies. These
results demonstrate that depletion of MK2 specifically
sensitizes p53-deficient cells to the antiproliferative effects
of chemotherapy-induced DNA damage.
We used Western blot analysis to profile activation of
the MK2 pathway and the p53 network following cisplatin
and doxorubicin treatment in these four cell lines (Fig-
ure 2A). The presence or absence of MK2 had no effect
on the strong induction of p53 and p21 following exposure
to cisplatin or doxorubicin in the p53WT/WT cells. Only
minimal amounts of the p53 inducer protein p19ARF were
detected. Neither p53 or p21 induction was detectable
in p53/MEFs in the presence or absence of MK2. How-
ever, the tumor suppressor p19ARF was strongly induced
in these cells even in the absence of DNA-damaging
chemotherapy, likely reflecting a feedback response due
to the inability of these cells to induce p53. Thus, we con-
cluded that MK2 is not required for the normal p53/p21
Cancer Cell
MK2-Dependent Checkpoints in p53-Defective CellsFigure 3. Depletion of MK2 Sensitizes p53-Deficient MEFs to the Antiproliferative Effects of Cisplatin and Doxorubicin by Inducing
Mitotic Catastrophe
p53WT/WT and p53/ MEFs stably expressing RNAi hairpins against luciferase (A and C) or MK2 (B and D) were treated with low-dose cisplatin
(1.0 mM) or doxorubicin (0.1 mM) for 30 hr, fixed and stained with antibodies against phospho-histone H3, g-H2AX, and cleaved caspase-3. Positive
staining for g-H2AX in combination with phospho-histone H3 and cleaved caspase-3 labeling is indicative of mitotic catastrophe and was only
observed inMK2-depleted p53/ cells ([D], arrows). The arrowhead in that panel shows a g-H2AX-positive cell that does not stain for either phospho-
histone H3 or cleaved caspase-3. Scale bar, 5 mm.induction or stabilization in response to DNA damage
in wild-type primary cells, and that MK2 is unable to in-
duce p21 expression after DNA damage in the absence
of functional p53.
Downregulation of MK2 Leads to Mitotic
Catastrophe after DNA Damage in p53/ Cells
We speculated that the reduced colony formation ob-
served in MK2-depleted p53/ MEFs after DNA-damag-
ing chemotherapy might be due to mitotic catastrophe
resulting fromdefective cell-cycle checkpoints. A hallmark
of mitotic catastrophe is entry of cells into mitosis despite
the presence of damaged DNA, resulting in activation of
the apoptotic cell death pathway (Castedo et al., 2004).
To investigate this, luciferase shRNA control and MK2-
depleted p53 wild-type or null MEFs were treated with
low doses of doxorubicin or cisplatin for 30 hr and immu-
nostained with antibodies against histone H3 pSer-10
as a marker for mitotic entry, histone g-H2AX as marker
for persistent DNA damage, and cleaved caspase-3 as a
marker for apoptosis (Figure 3). Luciferase shRNA-treated
p53WT/WT and p53/ cells showed robust g-H2AX foci
after exposure to DNA-damaging chemotherapy. No
phospho-histone H3 or cleaved caspase-3 staining was
observed in MK2-containing cells, consistent with an in-
tact DNA-damage response regardless of the presence
(Figure 3A) or absence (Figure 3C) of p53. Similarly, anCaintact DNA-damage checkpoint response was also ob-
served in MK2-depleted cells that contained wild-type
p53 (Figure 3B). In sharp contrast, however, in the MK2-
deficient p53/ cells, a substantial fraction of the
g-H2AX-positive cells also stained positively for both
phospho-histone H3 and cleaved caspase-3 (Figure 3D).
Interestingly, no caspase-3 staining was observed in
g-H2AX-positive cells that did not also contain phospho-
histone H3 (Figure 3D, arrow versus arrowhead). Thus, in
the absence ofMK2,p53null primary cells treatedwith cis-
platin and doxorubicin lose one or more critical cell-cycle
checkpoints and undergo mitotic catastrophe.
Downregulation of MK2 Causes Regression of
Established p53/ Tumors In Vivo after Low-Dose
Treatment with DNA-Damaging Agents
We investigated whether the chemo-sensitizing effect of
MK2 depletion in p53 null cells in culture could also be
observed when pre-existing p53-deficient tumors were
treated with DNA-damaging drugs in vivo. In these ex-
periments, H-Ras-V12-transformed p53/ MEFs were
stably transfected with control shRNA or MK2 shRNA
expressed from a murine U6 promoter, using a lentiviral
delivering system (Figure 4A; Figure S3). The lentiviral
transfer vector also encoded GFP under the control of
a CMV promoter, allowing for fluorescent detection of
tumors in situ. Tumors were induced by injection of 106ncer Cell 11, 175–189, February 2007 ª2007 Elsevier Inc. 179
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MK2-Dependent Checkpoints in p53-Defective CellsFigure 4. MK2 Depletion Enhances Regression of Established Tumors after DNA-Damaging Chemotherapy in a Murine Model
(A) H-Ras-V12-transformed p53/ MEFs (Ferbeyre et al., 2002) were infected with lentiviruses encoding U6 promoter-driven luciferase shRNA or
MK2 shRNA, and CMV promoter-driven GFP. Three days postinfection, GFP-expressing cells were selected by FACS and cultured for an additional
3 days. Efficiency of MK2 knockdown in the entire GFP-positive population was then assessed by immunoblotting of total cell lysates.
(B) Following subcutaneous injection of 106 shRNA-containing cells into the flanks of NCR nude outbred mice, tumor growth was measured every 2
days, starting at day 6 postinjection. Arrow indicates the start of intraperitoneal administration of DMSO, 2mg/kg cisplatin, or 4mg/kg doxorubicin on
day 12, given three times/week. Mean tumor sizes with error bars denoting standard deviation are shown. In the absence of DNA-damaging chemo-
therapy, the MK2-depleted tumors were statistically significantly larger than the control tumors at each time point beginning on day 13 (Student’s
t test, two-tailed, p < 0.02). In contrast, after cisplatin or doxorubicin treatment the MK2-depleted tumors were statistically smaller than the control
tumors beginning on days 21 and 23, respectively (p < 0.02).
(C) Upper panels: dorsal view of the tumors in situ 14 days after initiation of the indicated treatments, corresponding to 26 days after tumor cell
implantation. Middle panels: corresponding fluorescence images. Lower panels: close-up view of the excised tumors.
(D) Tumor weight was analyzed at the 26 day endpoint. Error bars denote standard deviation.cells into the flanks of nude mice. Twelve days later, 1
cm diameter tumors had formed at all injection sites,
and treatment with cisplatin, doxorubicin, or vehicle was
begun (Figure 4B). In the absence of treatment with
DNA-damaging drugs, the tumors arising from the MK2-
depleted cells in the right flanks of these animals grew
slightly larger than those of the luciferase shRNA control
cells in the left flanks (Figures 4B–4D). Following treatment
with cisplatin or doxorubicin, the control tumors showed
either minimal reduction in size, or slow continued growth
(Figures 4B and 4D, red symbols). In contrast, the MK2-
depleted tumors showed a dramatic reduction in weight
and diameter (Figures 4B and 4D, blue symbols). Tumors
depleted of MK2 shrank from 1.3 cm to 0.4 cm over 14
days when treated with cisplatin, and from 1.4 to 0.5 cm180 Cancer Cell 11, 175–189, February 2007 ª2007 Elsevier Inwhen treated with doxorubicin. Thus, the sensitizing effect
of MK2 depletion on DNA-damage-induced cell death in
p53-deficient primary cells observed in cell culture was
also maintained in vivo. These results strongly suggest
that MK2 may be a useful target for the design of cancer
treatment agents.
MK2 Is Required for the G2/M Checkpoint following
Doxorubicin Treatment in p53-Deficient Cells
To investigate the molecular mechanisms involved in
MK2-dependent responses to DNA lesions, we examined
cell-cycle profiles of control and MK2-depleted p53/
MEFs. Asynchronous MK2 or control knockdown p53/
MEFs were mock treated or exposed to doxorubicin
for 30 hr, and cell-cycle distribution was monitored byc.
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MK2-Dependent Checkpoints in p53-Defective CellsFACS. In one set of experiments, the spindle poison noco-
dazole was added to themedia 3 hr after addition of doxo-
rubicin, to cause any cells progressing through the cell
cycle to arrest in mitosis. DNA content was monitored by
PI staining; phospho-histone-H3 staining was used as an
indicator of mitotic entry. As shown in the left panels of
Figure 5A, treatment of control knockdown p53/ cells
with doxorubicin led to the accumulation of cells with 4N
DNA content, and a lack of phospho-histone H3 staining
in either the absence or presenceof nocodazole, indicative
of an intact G2/M checkpoint. These cells expressing
control shRNAs behaved identically to an untransfected
control p53/ cell population (Figures S4A and S4B). In
marked contrast, MK2-depleted p53/ cells treated with
doxorubicin displayed a cell-cycle profile similar to that
of untreated cells (Figure 5A, right upper and middle
panels), with only a small increase in the 4N peak com-
pared to the doxorubicin-treated luciferase shRNA con-
trols, a slightly increased S phase population, and the
appearance of a sub-G1 population indicative of apopto-
sis. Addition of nocodazole following doxorubicin treat-
ment to the MK2-depleted cells caused them to accumu-
late in a 4N DNA-containing peak, with 28.5% of the cells
staining positively for phospho-histoneH3 (Figure 5A, right
lower panels), a value similar to that of untreated p53/
cells blocked in mitosis with nocodazole (29.5%, Fig-
ure S4D). Intriguingly, MK2 depletion did not alter total
Chk1 levels or reduce Chk1 activation following DNA
damage (Figure 5B). These findings demonstrate that
loss of MK2 prevents p53-deficient cells from establishing
a functional G2/M checkpoint following doxorubicin-
induced DNA damage, despite the presence of activated
Chk1. Identical results were obtained using a second un-
related shRNA against MK2 (data not shown). Importantly,
the checkpoint defect could be fully rescued in the MK2-
depleted cells by expressing a shRNA-resistant form of
MK2 at levels comparable to those of the endogenous
protein (Figure S5).
Two Cdc25 family members, Cdc25B and -C, play
important roles in initiating and maintaining mitotic entry
in normal cells (Nilsson and Hoffmann, 2000) and are
prominent targets of the G2/M checkpoint (Donzelli and
Draetta, 2003). Cdc25B is believed to function by activat-
ing Cdk1/Cyclin B at the centrosome in late G2 as an initi-
ator of early mitotic events (Jackman et al., 2003), while
Cdc25C functions to further amplify Cdk1/CyclinB activity
within a nuclear autoamplification loop once mitosis
has begun (Hoffmann et al., 1993). In response to g- or
UV-irradiation-induced DNA damage, checkpoint kinases
phosphorylate Cdc25B and -C on Ser-323 and -216,
respectively, to induce their binding to 14-3-3 proteins,
sequestering them in the cytoplasm away from their cy-
clin/Cdk substrates (Forrest and Gabrielli, 2001; Graves
et al., 2001; Kumagai and Dunphy, 1999; Peng et al.,
1997). Recent studies by van Vugt et al. suggest that
Cdc25B plays a particularly crucial role in initiating and
maintaining normal cell-cycle G2/M checkpoint re-
sponses, since reactivation of Cdc25B is critical for DNA-
damaged cells to re-enter the cell cycle (van Vugt et al.,Ca2004). We therefore investigated whether MK2 signaling
was required for association of Cdc25B with 14-3-3 in
response to DNA damage by chemotherapeutic drugs.
As shown in Figure 5C, both doxorubicin and camptothe-
cin treatment resulted in the generation of stable 14-3-3-
binding sites on Cdc25B in the luciferase shRNA control
cells. No 14-3-3 binding of Cdc25B, however, was de-
tected in lysates from the MK2-depleted cells (Figure 5C,
lower panel). This result is in good agreement with the
cell-cycle studies in Figure 5A, which showed loss of the
G2/M checkpoint in MK2-depleted cells after treatment
with the topoisomerase inhibitor doxorubicin. These data
indicate that loss of theG2/Mcheckpoint after DNA lesions
in MAPKAP Kinase-2-depleted p53-defective cells likely
arises, at least in part, from loss of Cdc25B binding to
14-3-3 proteins.
MK2 Is Required for S Phase Checkpoint Arrest
following Cisplatin Treatment in p53-Deficient Cells
Treatment with the DNA intrastrand crosslinker cisplatin
caused p53/ cells to predominantly accumulate in S
phase of the cell cycle (Figure S4C). RNA interference
was used to investigate the role of MK2 in this process.
p53/ control knockdown cells showed an accumulation
in S phase after cisplatin exposure (Figure 6A, left middle
panels) identical to that seen in untransfected p53/ cells.
Addition of nocodazole to the luciferase knockdown cells 3
hr following cisplatin treatment did not reveal the appear-
ance of any mitotic cells over the ensuing 27 hr, as moni-
tored by phospho-histone H3 staining (Figure 6A, lower
left panels), indicating a functionally intact S phase check-
point. Depletion ofMK2 prior to cisplatin exposure resulted
in a dramatically different result. As seen in the right panels
of Figure 6A, MK2-depleted p53/ cells showed a cell-
cycle profile after cisplatin treatment that was similar to
that of untreated cells, other than a slight increase in the
total number of cells in S phase and the appearance of
a sub-G1 population consistent with apoptosis. Strikingly,
when nocodazole was added 3 hr following cisplatin
addition, the MK2-depleted p53/ cells accumulated in
a 4N DNA-containing peak with25% of the cells staining
positive for phospho-histone H3. The same cell-cycle
defectsafter cisplatinexposurewereobservedusingasec-
ond unrelated shRNA sequence against MK2 (data not
shown), and the MK2 shRNA phenotype was completely
reversed by expression of an RNAi-resistant form of MK2
at physiological levels (Figure S5). Similar to what was ob-
served following doxorubicin treatment (Figure 5B), MK2
depletion did not impair activation of Chk1 after cisplatin
exposure (Figure 6B). These data imply that MK2 is essen-
tial for the cisplatin-inducedSphase arrest in p53-deficient
cells, and that loss of MK2 enables these cells to override
the cisplatin-induced S phase checkpoint, despite the
presence of activated Chk1, and proceed into mitosis.
In contrast to the 14-3-3-mediated sequestration of
Cdc25Band -C involved in theG2/Mcheckpoint response,
the G1 and S phase checkpoints are largely controlled by
the phosphorylation-dependent degradation of another
Cdc25 isoform, Cdc25A (Bartek and Lukas, 2001; Businoncer Cell 11, 175–189, February 2007 ª2007 Elsevier Inc. 181
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MK2-Dependent Checkpoints in p53-Defective CellsFigure 5. MAPKAP Kinase-2 Mediates a G2/M Arrest following Doxorubicin Treatment
(A) RNAi downregulation of MK2 ablates the doxorubicin-induced G2/M checkpoint. p53
/MEFs stably expressing control luciferase shRNA (left) or
MK2 shRNA (right) were cultured in the absence or presence of 10 mMdoxorubicin, and cell-cycle profiles were analyzed 30 hr later by FACS using PI
for DNA content (blue) and phospho-histone H3 staining as an indicator of mitosis (red). In the lower set of panels, nocodazole (100 ng/ml) was added
3 hr following doxorubicin addition. Note that, in addition to loss of the prominent G2/M checkpoint, the G1 and S phase components are also
eliminated in MK2-depleted cells following doxorubicin + nocodazole treatment.
(B) Downregulation of MK2 does not impair Chk1 activation. Luciferase shRNA- or MK2 shRNA-expressing p53/ MEFs were mock treated or
exposed to 10 mMdoxorubicin or 10 mMcamptothecin for 30 hr. Total cell lysateswere immunoblotted for the presence ofMK2 and total and activated
forms of Chk1.
(C) Doxorubicin and camptothecin-induced binding of Cdc25B to 14-3-3 is lost in MK2-depleted cells. p53/ MEFs cells either expressing a lucif-
erase hairpin (upper panel) or aMK2-specific hairpin (lower panel) weremock treated or treated with 10 mMcamptothecin (cam) or 10 mMdoxorubicin
(dox) for 8 hr. The presence of 14-3-3-binding sites on Cdc25Bwasmonitored by incubating the lysates with bead-bound GST-14-3-3b/z followed by
immunoblotting of the pulled-down material.182 Cancer Cell 11, 175–189, February 2007 ª2007 Elsevier Inc.
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MK2-Dependent Checkpoints in p53-Defective CellsFigure 6. MK2 Controls the S Phase
Checkpoint in Response to Cisplatin
Treatment
(A) RNAi downregulation of MK2 ablates the
cisplatin-induced S phase checkpoint. p53/
MEFs stably expressing control luciferase
shRNA (left) or MK2 shRNA (right) were cul-
tured in the absence or presence of 10 mM cis-
platin, and cell-cycle profiles were analyzed 30
hr later by FACS using PI for DNA content (blue)
and phospho-histone H3 staining as an indica-
tor of mitosis (red). In the lower set of panels,
nocodazole (100 ng/ml) was added 3 hr follow-
ing cisplatin addition.
(B) Cisplatin-induced degradation of Cdc25A is
impaired in MK2-depleted cells despite acti-
vation of Chk1. Luciferase shRNA- or MK2
shRNA-expressing p53/ MEFs were mock
treated or exposed to 10 mM cisplatin for 8
and 12 hr. Total cell lysates were immunoblot-
ted for Cdc25A, total MK2, and activatedChk1.
b-actin was used as a loading control.et al., 2004). We therefore investigated whether MK2 was
required for the degradation of Cdc25A following cis-
platin-induced DNA damage (Figure 6B). Cdc25A levels
were undetectable in the control luciferase knockdown
cells after treatment with cisplatin. In contrast, in the
MK2-depleted cells, substantial amounts of Cdc25A re-
main present in the lysates after cisplatin exposure, indi-
cating that, in the absence of MAPKAP Kinase-2, p53/
MEFs cells are defective in targeting Cdc25A for degra-
dation in response to cisplatin-induced DNA damage.
This impaired ability of MK2-depleted cells to degrade
Cdc25A likely explains their failure to establish a sustained
G1/S checkpoint following cisplatin exposure. Interest-
ingly, Cdc25A may be a direct target of MK2 in vivo, since
bothMK2 andChk1 phosphorylate Cdc25A equivalently in
vitro (Figure S6), Chk1 phosphorylation of Cdc25A in vivo
hasbeenshown to facilitate its ubiquitin-mediatedproteol-
ysis in a complex and incompletely understood manner
(Jin et al., 2003; Mailand et al., 2000), and MK2 and Chk1
phosphorylate the identical optimal sequence motifs
when analyzed by oriented peptide library screening
(Manke et al., 2005).CMK2 and Chk1 Are Activated Independently by DNA
Damage and Are Both Potently Inhibited by UCN-01
Activation of MK2 by cisplatin, camptothecin, and doxoru-
bicin is strikingly similar to the activation profile reported for
Chk1 (Agner et al., 2005; Ho et al., 2005; Mailand et al.,
2000; Zhao and Piwnica-Worms, 2001). Similarly, the im-
paired S phase and G2/M checkpoints seen after these
DNA-damaging stimuli in MK2 knockdown cells bears
some resemblance to what has been previously reported
for Chk1-deficient p53-defective cells (Xiao et al., 2003).
These phenotypic similarities prompted us to further inves-
tigatewhether the activation ofChk1 andMK2was interde-
pendent.Asshown inFigures5Band6B, activationofChk1
in response to cisplatin and doxorubicin was unimpaired in
MK2-depleted cells. We therefore investigated the con-
verse—whether the activation of MK2 after DNA damage
was dependent on Chk1. U2OS cells depleted of Chk1 us-
ing siRNA were exposed to cisplatin and doxorubicin and
analyzed for activation of MK2. As shown in Figure 7A,
phosphorylation/activation of MK2 occurred normally after
treatment with these DNA-damaging agents, regardless of
the presence or absence of Chk1. Thus, activation of MK2ancer Cell 11, 175–189, February 2007 ª2007 Elsevier Inc. 183
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(A) MK2 is activated independently of Chk1. U2OS cells were either transfected with Chk1-specific siRNA oligonucleotides or GFP control oligonu-
cleotides, and MK2 activation was monitored after treatment with cisplatin (10 mM) or doxorubicin (10 mM). Cell lysates were probed for total and
phosphorylated/activated forms of MK2 with an antibody detecting total Chk1, to monitor the knockdown efficiency.
(B) In vitro kinase assayswere performedwith Chk1 andMK2 in the presence of increasing doses of UCN-01 usingMK2-tide as a substrate. Results of
nR 3 experiments are shown with error bars denoting standard error of the mean.
(C) Structural basis for UCN-01 inhibition of MK2. Ribbon diagrams (b strands shaded yellow, a helices shaded red, loops shaded green) and
molecular surfaces of the Chk1:UCN-01 complex (C1 and C4) and the MK2:staurosporine complex with UCN-01 modeled onto staurosporine
(C2, C3, and C5). (C3) is rotated 90 from the view in (C2); the staurosporine molecule is colored purple, and UCN-01 is shown with carbon atoms
colored cyan, oxygen colored red, and nitrogen colored blue. The arrow points to the unique 7-hydroxy group of UCN-01, with Van der Waals radii
indicated by dots.
(D) UCN-01 inhibits MK2 in U2OS cells. Luciferase shRNA- or MAPKAP Kinase-2 shRNA-expressing cells were incubated at 37C or 42C for 2 hr in
the absence or presence of 250 nM UCN-01. Cells were lysed and probed for total hsp-27, hsp-27 pS82, and MK2 by immunoblotting.
(E) UCN-01 inhibition of hsp-27 is independent of Chk1. GFP or Chk1 siRNA-transfected U2OS cells were incubated at 42C or 37C for 2 hr in the
absence or presence of 250 nM UCN-01. Cells were then lysed and probed for total hsp-27, hsp-27 pS82, and Chk1 by immunoblotting.and activation of Chk1 after drug-induced DNA damage
appear to occur independently of each other, and both
kinases appear to participate in parallel DNA-damage
checkpoint signaling pathways that are necessary for cell
survival in the absence of a strong p53 response.
The staurosporine derivative 7-hydroxystaurosporin/
UCN-01 has been shown to increase the cytotoxicity of184 Cancer Cell 11, 175–189, February 2007 ª2007 Elsevier Incchemotherapy and radiation (Mack et al., 2004; Shao
et al., 2004; Tse and Schwartz, 2004) and is currently in
clinical trials. It has been demonstrated that a major target
of UCN-01 is the checkpoint kinase Chk1 (Busby et al.,
2000; Graves et al., 2000), leading to speculation that
the increased chemosensitivity and radiation sensitivity
of cells treated with UCN-01 is a direct result of.
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UCN-01 inhibits Chk1 with an IC50 that is1000 fold lower
than that for Chk2, and hence has been used experimen-
tally as a Chk1-specific inhibitor (Graves et al., 2000;
Syljuasen et al., 2005). Strong circumstantial evidence,
however, suggests that UCN-01 must be inhibiting other
kinases involved in cell-cycle control at similar concen-
trations as those used for Chk1 inhibition studies. For
example, Chk1-depleted cells maintain phosphorylation
of Ser-216, a well-characterized Chk1 target site on
Cdc25C, both during asynchronous growth and following
g-irradiation (Graves et al., 2000; Zhao et al., 2002b). Phos-
phorylation at this site is lost, however, when cells are
treated with low doses of UCN-01 (300 nM) (Busby
et al., 2000; Graves et al., 2001), indicating that UCN-01 in-
hibitable kinase(s) other than Chk1 participate in Cdc25C
Ser-216 phosphorylation. Based on our finding that MK2
depletion results in a dramatically increased chemosensi-
tivity of malignant cells, we asked whether MK2 might be
a UCN-01 target, similar to Chk1. In vitro kinase assays
were performed under identical reaction conditions with
Chk1 and MK2 using the same optimal peptide substrate
for both kinases with the core consensus sequence L-Q-
R-Q-L-S-I (Manke et al., 2005), in the presence of various
concentrations of UCN-01. As shown in Figure 7B, UCN-
01 potently inhibited both kinases, with an IC50 value of
35 nM for Chk1 and 95 nM for MAPKAP Kinase-2.
The IC50 valuewemeasured forChk1 is in good agreement
with previously published data (Graves et al., 2000; Jack-
son et al., 2000). Importantly, the IC50 value we measured
for MK2 is significantly below the concentrations of UCN-
01 that are used in ‘‘Chk1-specific’’ checkpoint abrogation
assays, suggesting that, under the conditions used in
those studies, both Chk1 and MK2 were being inhibited.
To examine the structural basis for UCN-01 inhibition of
MK2, the structure of the MK2:UCN-01 complex was
modeled using coordinates from thepublishedMK2:staur-
osporine structure (Underwoodet al., 2003) andcompared
the results with the cocrystal structure of Chk1:UCN-01
(Zhao et al., 2002a) (Figure 7C). As seen in Figures 7C2,
7C3, and 7C5, the 7-hydroxy moiety of UCN-01 can be
easily accommodated into the MK2:staurosporine struc-
ture, where its closest neighboring residues would be
Val-118 (2.8 A˚ to Cg2), Leu-141 (3.2 A˚ to Cd1), and Thr-
206 (3.6 A˚ to Cg2). Lack of steric hindrance, and the overall
similarity of the modeled MK2:UCN-01 structure to the
Chk1:UCN-01 structure (Figures 7C1 and 7C4), provide
a structural rationale for the tight binding observed
biochemically.
To verify that MK2 is a direct target of UCN-01 within
cells, we measured the phosphorylation of the MK2 sub-
strate hsp-27 (Landry et al., 1992) after heat shock, a stim-
ulus that activates the p38MAPK/MK2 pathway (Rouse
et al., 1994). Control or MK2 shRNA-expressing U2OS
cells were incubated at 42C or 37C for 2 hr in the pres-
ence or absence of 250 nM UCN-01, and phosphorylation
of hsp-27 was monitored by immunoblotting. Figure 7D
shows that hsp27 was phosphorylated on Ser-82 when
the control luciferase shRNA cells were placed at 42CCa(Figure 7D, lane 1). This phosphorylation was completely
abrogated by treatment with UCN-01 (Figure 7D, lane 2).
No phosphorylation was observed in MK2 knockdown
cells placed at 42C, regardless of the presence or ab-
sence of UCN-01 (Figure 7D, lanes 3 and 4), and no signal
was observed in both the control and MK2 knockdown
cells that were maintained at 37C, with or without UCN-
01 treatment (Figure 7D, lanes 5–8). Heat shock was
equally effective in promoting the phosphorylation of
hsp-27 on Ser-82, and UCN-01 was equally effective in
blocking Ser-82 phosphorylation in cells that were de-
pleted of Chk1 (Figure 7E, lanes 1–4). Thus, UCN-01 in-
hibits MK2 in vivo, and this effect is independent of Chk1
function. These data demonstrate that UCN-01 is a direct
inhibitor of MK2 within cells and indicate that the clinical
efficacy of UCN-01 in cancer treatment, particularly in
p53-defective tumors, likely arises from the simultaneous
inhibition of both the Chk1 and MK2 signaling pathways.
DISCUSSION
Activation of cell-cycle checkpoints in response to various
types of DNA damage is essential for the maintenance of
genomic stability in eukaryotic cells. Disruption of normal
checkpoint function from inherited and acquired genetic
mutations is increasingly recognized as a pathophysiolog-
ical mechanism responsible for tumor-prone human dis-
ease syndromes (Bartek and Lukas, 2003; Kastan and
Bartek, 2004;O’Driscoll et al., 2004; Shiloh, 2003). Alterna-
tively, the lossof normalDNA-damagecheckpoint function
in tumor cells is thought to underlie their increased suscep-
tibility to genotoxic agents used in cancer chemotherapy.
This has led to the suggestion of therapeutically targeting
the remaining checkpoint pathways in tumors to increase
the tumor-specific toxicity of DNA-damaging chemother-
apy, particularly in cells that lack a functional p53 response
(Dixon and Norbury, 2002; Kawabe, 2004; Zhou and
Bartek, 2004).
The DNA-damage response has largely been defined in
the context of the ATM-Chk2 pathway and the ATR-Chk1
pathway. In contrast to Chk1 and Chk2, which are dedi-
cated to DNA-damage-response signaling, the p38MAPK
pathway is a general stress response pathway that senses
a wide variety of aberrant cell states. We found that both
topoisomerase inhibitors and intrastrand crosslinking
agents activated MK2 in a p38MAPK-dependent manner
downstream of ATM and ATR. The kinetics of MK2 activa-
tion was observed to parallel the appearance of g-H2AX
foci. Rapid foci formation and MK2 activation was seen
after cisplatin and doxorubicin exposure. In contrast,
both foci formation and MK2 activation were delayed by
4 hr after camptothecin treatment, a finding that is in
goodagreementwith previous data showing thatDNA rep-
lication/S phase progression is required for generation of
a DNA lesion by this topoisomerase I inhibitor (Pommier,
1996; Tsao et al., 1992). Thus, in response to these geno-
toxic agents, the p38MAPK-MK2 signaling axis appears to
be activated through the direct sensing of DNA damage.
Thismechanismof stress kinasepathwayactivation differsncer Cell 11, 175–189, February 2007 ª2007 Elsevier Inc. 185
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ing of Cell-Cycle Checkpoint Pathways
in p53-Proficient and -Deficient Cells
(A) Checkpoint function in p53-proficient cells
is mediated primarily through a robust, sus-
tained p53 response downstream of ATM,
together with Chk1. Although not shown
explicitly in the diagram, Chk1 also directly
phosphorylates p53 (Shieh et al., 2000). Under
these conditions the presence of MK2 is not
required for cell survival after exposure to
DNA-damaging agents.
(B) In p53-deficient cancer cells, checkpoint
signaling following exposure toDNA-damaging
agents is mediated through the combined ac-
tion of both the Chk1 and the p38MAPK/MK2
pathways. In this situation the p38MAPK/MK2
branch of checkpoint signaling becomes
essential for cell survival after DNA damage.
Both pathways are simultaneously inhibited
by the indolocarbazole drug UCN-01.significantly from that observed following exposure to UV
light, which did not require ATM or ATR, since it was acti-
vated equally well in cells that were genetically deficient
for these DNA-damage kinases. In agreement with our
observations, Bulavin et al. reported that activation of
p38MAPK was unaffected by treatment of HeLa cells with
caffeine, a nonspecific inhibitor of several PI 3-Kinase-like
Kinases (PIKKs), prior toUV irradiation (Bulavin et al., 2001).
The requirement for particular upstream PIKKs to acti-
vate MK2 was different for different DNA-damaging
agents. In response to lesions created by cisplatin and
camptothecin, activation of p38MAPK and MK2 required
ATR,while the double-strand-break-inducing topoisomer-
ase II inhibitor required both ATM and ATR. This latter find-
ing is consistent with a recent study by Jazayeri et al.
(2006), which showed that both ATM and Mre11 are re-
cruited to DNA double-strand breaks, converting them
into RPA-coated single-strand DNA, which then recruits
ATR. In mammalian cells, p38MAPK consists of four iso-
forms—a, b, g, and d, only two of which, a and b, are in-
hibited by SB203580 (Lee et al., 1999). Our finding that
SB203580 inhibited the activation of MK2 in response to
all of the DNA-damaging drugs investigated implicates
either or both of these isoforms as the relevant upstream
activating kinase. The manner by which ATR, or possibly
ATM, activates p38MAPK is unclear but may involve acti-
vation of any of a variety of MAPKK and MAPKKKs that
are known to participate in p38MAPK activation in other
contexts (Brancho et al., 2003; Lee et al., 1999).
A particularly striking observation was the synthetic le-
thal interaction between p53 andMK2. On a systems level,
this indicates a rewiring of DNA-damage checkpoint
signaling from a predominately p53 and Chk1-mediated
arrest in p53-proficient cells (Lam et al., 2004) toward
a Chk1- and p38MAPK/MK2-driven response in p53-defi-
cient cells (Figure 8). We found that MK2 was critical both
forCdc25Bbinding to 14-3-3proteins after topoisomerase
inhibition and for establishment of a stable G2/M check-186 Cancer Cell 11, 175–189, February 2007 ª2007 Elsevier Incpoint in p53/ cells exposed to doxorubicin. The 14-3-
3-binding site of Cdc25B is a direct substrate for MK2
(Lemaire et al., 2006; Manke et al., 2005), and Cdc25B
function, which is inhibited by 14-3-3 binding (Forrest
and Gabrielli, 2001), is required for cell-cycle escape
from the checkpoint after genotoxic stress (Bugler et al.,
2006; Forrest and Gabrielli, 2001; van Vugt et al., 2004).
Although Cdc25B is critical for mitotic control in normal
cells (Dutertre et al., 2004; Lindqvist et al., 2005), Piwn-
ica-Worms and colleagues have recently shown that
Cdc25A, or some other as-yet-unknown phosphatase,
appears to be able to compensate for the cell-cycle and
checkpoint functions of Cdc25Band -C inmice genetically
deficient for both of these phosphatases (Ferguson et al.,
2005). We also observed that MK2 was critical for S phase
arrest after cisplatin treatment. In the absence of MK2,
Cdc25A, a critical effector of these cell-cycle transitions,
failed to undergo complete damage-induced destruction.
The loss of these MK2-dependent cell-cycle checkpoints
permits cellswithbrokenordamagedDNAstrands toenter
mitosis, resulting in mitotic catastrophe. Consequently,
depletion of MK2 using RNA interference resulted in
a profound increase in the sensitivity of p53/ cells to
the antiproliferative effects of both cisplatin and doxorubi-
cin. These effects were observed in clonogenic survival
assays in culture, and in a xenograft tumor model in vivo.
Intriguingly, there appears to be an additional feedback
connection between the MK2 and p53 pathways, since
Weber et al. reported that MK2 could directly phosphory-
late HDM2, the E3 ubiquitin ligase responsible for p53
destruction, to impair its function (Weber et al., 2005). In
that study, p53-competent MK2-deficient cells showed
elevated levels of p53 and increased apoptosis after UV
irradiation. We similarly observed a modest increase in
p53 levels in MAPKAP Kinase-2-depleted p53+/+ MEFs,
compared to control shRNA-treated p53+/+ MEFs after
treatment with doxorubicin or cisplatin, along with a slight
decrease in survival, but this failed to reach statistical.
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those of Weber et al. could be due to residual MK2 activity
using our RNAi approach compared to their gene disrup-
tion approach, or to the use of different genotoxic agents,
since our data indicate that UV-induced activation of MK2
occurs independently of the ATR/ATM-mediated DNA-
damage response that is activated by doxorubicin and
cisplatin.
Recruitment of MK2 as a critical DNA-damage check-
point kinase pathway in p53-deficient cells, but not in
p53-proficient cells, suggests that inhibition of MK2 will
likely function synergistically with conventional chemo-
therapeutic agents in human cancer treatment, similar to
what has been proposed for inhibitors of Chk1 (Kawabe,
2004). UCN-01 is an indolocarbazole ATP analog that
inhibits Chk1 and increases the sensitivity of tumor cells
to the antiproliferative action of cisplatin, camptothecin,
and doxorubicin (Bunch and Eastman, 1996; Shao et al.,
1997;Wang et al., 1996).We found that UCN-01 is a potent
inhibitor of MK2 with an IC50 similar to that required for
Chk1 inhibition. Typical concentrations of UCN-01 used
in many cell-cycle checkpoint abrogation experiments
would have inhibited both Chk1 andMK2. This dual inhibi-
tion mechanism may provide a molecular rationale for the
efficacy of UCN-01 in cancer therapy, particularly underly-
ing its effectiveness in tumor cells that are defective in p53
function (Redkar et al., 2004; Wang et al., 1996), and sug-
gests that similar agents that simultaneously target two
distinct DNA-damage signaling pathways will prove to be
particularly efficacious. However, since disruption of the
MK2 signaling pathway enhances chemotherapeutic re-
sponses in p53-deficient cells, but not in p53-proficient
cells, even in the presence of a functional Chk1 response,
and since MK2 knockout mice are viable (Kotlyarov et al.,
1999), in contrast to Chk1 knockout mice (Liu et al.,
2000; Takai et al., 2000), our results suggest that a MK2-
specific inhibitor might provide significant clinical benefit
with fewer undesirable side effects, although we cannot
dismiss the possibility that the apparently normal survival
of the MK2 knockout mice results from compensation by
other genes with redundant function. The results of the
current study strongly support the development of clinical
MK2 inhibitors as viable anticancer agents and suggest
that such drugs are likely to be particularly efficacious for
the treatment of human p53-defective human cancers.
EXPERIMENTAL PROCEDURES
RNAi
The sequences used for shRNA and siRNA were as follows: luciferase
(shRNA), 50-pTGACCAGGCATTCACAGAAATTCAAGAGATTTCTGTG
AATGCCTGGTCTTTTTTC-30; mMK2 (shRNA#1), 50-pTCGATGCGTG
TTGACTATGATTCAAGAGATCATAGTCAACACGCATCGTTTTTTC-30;
mMK2 (shRNA#2), 50-pTGGAGAGCTCTTTAGTCGAATTCAAGAGATT
CGACTAAAGAGCTCTCCTTTTTTC-30; hMK2 (shRNA#1), 50-pTTGAC
CATCACCGAGTTTATTTCAAGAGAATAAACTCGGTGATGGTCATTTT
TTC-30; hMK2 (shRNA#2), 50-pTCAATGCGCGTTGACTACGATTCAA
GAGATCGTAGTCAACGCGCATTGTTTTTTC-30. The murine shRNAs
were used in MEFs, while the human shRNAs were used in U2OS
cells. Additional RNAi sequences include the following: GFP (siRNA)
sense,50-UCCCGGCUAUGUGCAGGAGdTdT-30, andantisensestrand,C50-CUCCUGCACAUAGCCGGGAdTdT-30; Chk1 (siRNA), 50-UGGCAA
CAGUAUUUCGGUAdTdT-30, and antisense strand 50-UACCGAAAUA
CUGUUGCCAdTdT-30. RNAi-resistant mMK2 was constructed by
changing the sequence starting at nucleotide 1041 from 50-ACGATGC
GTGTTGACTATGA-30 to 50-ACAATGACCATTGATTACGA-30 as de-
scribed in the Supplemental Experimental Procedures.
Murine Tumor Model
For tumor regression assays, H-Ras-V12-transformed p53/ MEFs
were stably transfected with a lentiviral transfer vector encoding for
shRNA targeting either MK2 or luciferase. A total of 106 cells in 0.1 ml
of PBS were injected subcutaneously into the flanks of nude mice
(Ncr nu/nu, Taconic), and tumors were allowed to form for 12 days.
Mice were then treated with either cisplatin (2 mg/kg, intraperitoneal
administration 33 per week) or doxorubicin (4 mg/kg, intraperitoneal
administration 33 per week), monitored for a total of 26 days, and
then sacrificed. Tumor diameter was measured periodically during
growth, and tumors were weighed at the endpoint. Experiments were
performed in quadruplicate, and data were plotted as sample means
with error bars showing standard deviation. These experiments were
approved by the Massachusetts Institute of Technology Committee
on Animal Care (CAC).
A more detailed description of the Experimental Procedures is
provided in the Supplemental Data.
Kinase Assays
In vitro kinase assays for UCN-01 IC50 determination for both Chk1 and
MK2 were performed in identical 30 ml reactions containing 20 mM
HEPES (pH 7.5), 10 mM MgCl2, 3 mM 2-mercaptoethanol, 100 mg/ml
BSA, 50 mM ATP, 10 mCi 32P-g-ATP, and 50 mM MK2-tide substrate
(Manke et al., 2005) for 20 min at 30C. Chk1 was used at a concentra-
tion of 0.3 mM, MK2 was used at a concentration of 0.1 mM. Reactions
were terminatedby adding an equal volumeof 0.5%phosphoric acid to
the reaction, and 5 ml was spotted onto P81 paper. After being washed
53 in 0.5% phosphoric acid, samples were subjected to scintillation
counting.
Molecular Modeling
The structure of MK2 bound to UCN-01 was modeled using PyMOL
with the structure of MK2 bound to staurosporine (PDB ID 1NXK
[Underwood et al., 2003]) as a base model.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and six supplemental figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/11/2/175/DC1/.
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